Monopar Therapeutics (MNPR) to Release Quarterly Earnings on Thursday

Monopar Therapeutics (NASDAQ:MNPR) is projected to issue its quarterly earnings data before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.37) per share for the quarter.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $37.60 on Tuesday. The company has a 50 day simple moving average of $37.39 and a two-hundred day simple moving average of $23.06. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30. The company has a market capitalization of $229.44 million, a price-to-earnings ratio of -19.09 and a beta of 1.18.

Analyst Upgrades and Downgrades

MNPR has been the topic of several analyst reports. HC Wainwright boosted their target price on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler reaffirmed an “overweight” rating and issued a $76.00 price target on shares of Monopar Therapeutics in a research report on Wednesday, March 19th.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.